Skip to content
Homepage
Author:
Tvardi Therapeutics
Posted Date:
August 14, 2026
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Tvardi Therapeutics
August 14, 2026
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
Tvardi Therapeutics
August 12, 2026
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
Tvardi Therapeutics
July 30, 2026
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
Tvardi Therapeutics
July 7, 2026
Tvardi Therapeutics to Participate in Upcoming Investor Events
Tvardi Therapeutics
May 22, 2026
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
Tvardi Therapeutics
May 20, 2026
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
Tvardi Therapeutics
April 2, 2026
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Tvardi Therapeutics
March 31, 2026
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
Tvardi Therapeutics
February 12, 2026
